PARP1P2

Across TCGA pan-cancer cohorts, PARP1P2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated PARP1P2 data layer.

The strongest signal is observed in kidney chromophobe (KICH), where higher PARP1P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARP1P2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, PAAD, and KIRC are the cancer types where PARP1P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Tertile	All	0.081	0.904	<.001	90	view →
PAAD	OS	Tertile	II,III,IV	0.146	0.557	<.001	72	view →
KIRC	OS	Tertile	II,III,IV	0.092	0.806	<.001	72	view →
LGG	OS	Tertile	All	0.584	0.900	<.001	36	view →
LUSC	DFS	Tertile	II,III,IV	0.156	0.673	.013	21	view →
SKCM	DFS	Tertile	III,IV	0.058	0.648	.001	18	view →
STAD	DFS	Tertile	All	0.446	0.643	.033	9	view →
UCEC	DFS	Tertile	All	1.000	0.892	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PARP1P2–KICH (DFS)

Open the KICH breakdown →